GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncimmune Holdings PLC (LSE:ONC) » Definitions » EPS (Diluted)

Oncimmune Holdings (LSE:ONC) EPS (Diluted) : £0.11 (TTM As of Feb. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Oncimmune Holdings EPS (Diluted)?

Oncimmune Holdings's Earnings per Share (Diluted) for the six months ended in Feb. 2024 was £0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 was £0.11.

Oncimmune Holdings's EPS (Basic) for the six months ended in Feb. 2024 was £0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Feb. 2024 was £0.11.

Oncimmune Holdings's EPS without NRI for the six months ended in Feb. 2024 was £0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Feb. 2024 was £0.11.

During the past 3 years, the average EPS without NRIGrowth Rate was 15.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 12 years, Oncimmune Holdings's highest 3-Year average EPS without NRI Growth Rate was 15.70% per year. The lowest was -43.00% per year. And the median was -18.75% per year.


Oncimmune Holdings EPS (Diluted) Historical Data

The historical data trend for Oncimmune Holdings's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncimmune Holdings EPS (Diluted) Chart

Oncimmune Holdings Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 Aug23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.13 -0.13 -0.08 - 0.06

Oncimmune Holdings Semi-Annual Data
May14 Nov14 May15 Nov15 May16 Nov16 May17 Nov17 May18 Nov18 May19 Nov19 May20 Nov20 May21 Nov21 May22 Feb23 Aug23 Feb24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 - -0.06 0.11 -

Competitive Comparison of Oncimmune Holdings's EPS (Diluted)

For the Biotechnology subindustry, Oncimmune Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncimmune Holdings's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncimmune Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where Oncimmune Holdings's PE Ratio falls into.



Oncimmune Holdings EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Oncimmune Holdings's Diluted EPS for the fiscal year that ended in Aug. 2023 is calculated as

Diluted EPS (A: Aug. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(4.104-0)/72.575
=0.06

Oncimmune Holdings's Diluted EPS for the quarter that ended in Feb. 2024 is calculated as

Diluted EPS (Q: Feb. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-1.099-0)/74.142
=-0.01

EPS (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncimmune Holdings  (LSE:ONC) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Oncimmune Holdings EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Oncimmune Holdings's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncimmune Holdings (LSE:ONC) Business Description

Traded in Other Exchanges
Address
1 Park Row, MediCity - D6 Building, Leeds, GBR, LS1 5AB
Oncimmune Holdings PLC is engaged in diagnosing cancer. It is involved in the development, manufacture, and commercialization of personalized immunodiagnostics for the screening, detection and care of cancer. The company's operating segment includes Early CDT Lung and ImmunoINSIGHTS.

Oncimmune Holdings (LSE:ONC) Headlines

No Headlines